Breast Cancer Stem Cells: We've Got Them Surrounded

Overview

Journal Clin Cancer Res

Specialty Oncology

Date 2012 Dec 20

PMID 23251003

Citations 21

Authors

Hasan Korkaya

Max S Wicha

Affiliations

Soon will be listed here.

Abstract

Breast cancer stem cells are regulated by cell intrinsic pathways as well as by elements in the tumor microenvironment. New evidence suggests that an important interaction between the interleukin (IL)-8 receptor CXCR1/2 and HER2 is involved in this regulation. Simultaneous targeting of these pathways provides a novel therapeutic approach.

Citing Articles

Stem Cell Origin of Cancer: Clinical Implications beyond Immunotherapy for Drug versus Therapy Development in Cancer Care.

Tu S, Trikannad A, Vellanki S, Hussain M, Malik N, Singh S Cancers (Basel). 2024; 16(6).

PMID: 38539487 PMC: 10969562. DOI: 10.3390/cancers16061151.

Stem Cell Theory of Cancer: Clinical Implications of Epigenomic versus Genomic Biomarkers in Cancer Care.

Tu S, Chen J, Singh S, Aydin A, Gokden N, Tam N Cancers (Basel). 2023; 15(23).

PMID: 38067237 PMC: 10705798. DOI: 10.3390/cancers15235533.

Pharmacological targeting PTK6 inhibits the JAK2/STAT3 sustained stemness and reverses chemoresistance of colorectal cancer.

Liu C, Pan Z, Chen Q, Chen Z, Liu W, Wu L J Exp Clin Cancer Res. 2021; 40(1):297.

PMID: 34551797 PMC: 8456648. DOI: 10.1186/s13046-021-02059-6.

Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment.

Koschorke A, Faraci S, Giani D, Chiodoni C, Iorio E, Canese R Cell Oncol (Dordr). 2019; 42(6):815-828.

PMID: 31376137 DOI: 10.1007/s13402-019-00464-w.

HER2 in stemness and epithelial-mesenchymal plasticity of breast cancer.

Voutsadakis I Clin Transl Oncol. 2018; 21(5):539-555.

PMID: 30306401 DOI: 10.1007/s12094-018-1961-x.

References

Korkaya H, Paulson A, Charafe-Jauffret E, Ginestier C, Brown M, Dutcher J . Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol. 2009; 7(6):e1000121. PMC: 2683567. DOI: 10.1371/journal.pbio.1000121. View

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

Iliopoulos D, Hirsch H, Struhl K . An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell. 2009; 139(4):693-706. PMC: 2783826. DOI: 10.1016/j.cell.2009.10.014. View

Aceto N, Duss S, MacDonald G, Meyer D, Roloff T, Hynes N . Co-expression of HER2 and HER3 receptor tyrosine kinases enhances invasion of breast cells via stimulation of interleukin-8 autocrine secretion. Breast Cancer Res. 2012; 14(5):R131. PMC: 4053109. DOI: 10.1186/bcr3329. View

Benoy I, Salgado R, van Dam P, Geboers K, Van Marck E, Scharpe S . Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res. 2004; 10(21):7157-62. DOI: 10.1158/1078-0432.CCR-04-0812. View

Ginestier C, Liu S, Diebel M, Korkaya H, Luo M, Brown M . CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest. 2010; 120(2):485-97. PMC: 2810075. DOI: 10.1172/JCI39397. View

Singh J, Farnie G, Bundred N, Simoes B, Shergill A, Landberg G . Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms. Clin Cancer Res. 2012; 19(3):643-56. PMC: 4868141. DOI: 10.1158/1078-0432.CCR-12-1063. View

Korkaya H, Kim G, Davis A, Malik F, Henry N, Ithimakin S . Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell. 2012; 47(4):570-84. PMC: 3432419. DOI: 10.1016/j.molcel.2012.06.014. View

Magnifico A, Albano L, Campaner S, Delia D, Castiglioni F, Gasparini P . Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab. Clin Cancer Res. 2009; 15(6):2010-21. DOI: 10.1158/1078-0432.CCR-08-1327. View

10.

Korkaya H, Paulson A, Iovino F, Wicha M . HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene. 2008; 27(47):6120-30. PMC: 2602947. DOI: 10.1038/onc.2008.207. View

11.

Korkaya H, Liu S, Wicha M . Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Invest. 2011; 121(10):3804-9. PMC: 3223613. DOI: 10.1172/JCI57099. View

12.

Efimova E, Liang H, Pitroda S, Labay E, Darga T, Levina V . Radioresistance of Stat1 over-expressing tumour cells is associated with suppressed apoptotic response to cytotoxic agents and increased IL6-IL8 signalling. Int J Radiat Biol. 2009; 85(5):421-31. PMC: 2690884. DOI: 10.1080/09553000902838566. View